The US trial pool
Section 6.1 of the Victoza® label pools five glycemic control trials in adults, each comparing liraglutide with placebo. In that pool, 1,673 adults received Victoza® for a mean of 37.3 weeks. They were 58 years old on average, had lived with diabetes for about nine years and started with a mean HbA1c of 8.4%. The label adds that a 52-week trial in patients aged 10 and older was also assessed, and that the type and severity of reactions in those young people were comparable to adults. [1]
These figures describe adults with type 2 diabetes on 1.2 mg or 1.8 mg a day. The label itself notes that trial rates cannot be compared directly with another drug’s trials and may differ from everyday care. [1]
| Group | People in group | Reported nausea |
|---|---|---|
| Placebo | 661 | 5% |
| Liraglutide 1.2 mg | 645 | 18% |
| Liraglutide 1.8 mg | 1,024 | 20% |
Europe and Canada fill in the detail
The European summary of product characteristics puts nausea in its very common class, meaning at least 1 in 10 people, and says digestive reactions tend to be more frequent at the start and usually lessen within a few days or weeks. [2] The Canadian monograph prints each trial separately and counts every event reported by at least 1% of people, whatever the investigator thought caused it. [3] That makes the background rate in the comparison arms visible.
| Trial and background | Victoza® | Comparison |
|---|---|---|
| LEAD-2, 26 weeks, with metformin [3] | 0.6 mg 10.7%; 1.2 mg 16.3%; 1.8 mg 18.6% | Placebo 4.1%; glimepiride 3.3% |
| LEAD-5, 26 weeks, with metformin and glimepiride [3] | 1.8 mg 13.9% | Placebo 3.5%; insulin glargine 1.3% |
| Trial 1860, 26 weeks, with metformin [3] | 1.2 mg 20.8%; 1.8 mg 27.1% | Sitagliptin 4.6% |
| LEAD-3, 52 weeks, Victoza® alone [3] | 1.2 mg 27.5%; 1.8 mg 29.3% | Glimepiride 8.5% |
| LEADER, median 3.5 years on treatment, high cardiovascular risk [1][3] | 3.7% | Placebo 0.9% |
| EU frequency class [2] | Very common (1 in 10 or more) | — |
When it tends to happen
Timing is where the Canadian data are most useful. Across the pooled long-term trials, roughly 13% of people on Victoza® and 2% on comparators reported nausea in the first two weeks. [3] In trial 1860 the first-fortnight figures were 16.3% on 1.2 mg and 17.4% on 1.8 mg, against 2.7% on sitagliptin. [3] In trial 1842, 18.9% of people on 1.8 mg with metformin reported nausea during the first 12 weeks, but only 1.9% did so during the following 52 weeks. [3]
The US label says withdrawals for stomach and bowel reactions happened mainly in the first two to three months. [1] The European leaflet describes nausea as something that usually goes away over time. [2] For most people, then, the pattern is an early peak during the dose steps, not a steady effect for as long as the medicine is used.
Who is more likely to feel it
Background medicine matters. In European data, 20.7% of people taking liraglutide with metformin reported at least one episode of nausea, compared with 9.1% when it was combined with a sulfonylurea. [2] A systematic analysis of 32 published phase 3 trials of GLP-1 medicines, with liraglutide as one of its reference drugs, also found more nausea and vomiting when metformin was the background treatment, and a clear link between higher doses and more nausea. [4] That is an analysis of published trials, not a test of individual patients, so it describes averages.
Age and kidney function are named too. The EU product information says people over 70 and those with mild or moderate kidney impairment may have more digestive effects on liraglutide. [2] Canada adds that the rate of digestive events rose with age, especially at 1.8 mg. [3] For young people, the paediatric trial behind the 10-and-over approval found more digestive side effects with liraglutide than with placebo. [11]
Why it might happen
Label-supported: the US prescribing information says liraglutide delays gastric emptying as part of how it lowers blood sugar after meals. [1] The EU text calls this a minor delay. [2] Food leaving the stomach more slowly is the most direct, documented link between Victoza® and feeling sick.
Studied but not settled: in a five-week crossover trial in adults with obesity but without diabetes, liraglutide 1.8 mg, the top Victoza® dose, increased feelings of fullness and reduced hunger; its effect on stomach emptying over five hours was equivalent to placebo, with a smaller, non-significant slowing in the first hour. [5] That population differs from Victoza® users, and the trial did not measure nausea as its main outcome, so it hints at a mechanism rather than proving one.
General medicine: MedlinePlus names “glutides”, medicines used for diabetes or obesity, among the treatments that commonly cause nausea and vomiting. [6]
Other causes to keep in mind
Nausea has many sources that have nothing to do with an injection. MedlinePlus lists stomach infections, food poisoning, reflux, migraine, pregnancy, motion sickness, severe pain such as kidney stones and slow stomach emptying, and it names appendicitis and bowel blockage among the serious problems that can begin with nausea. [6] Diabetes itself is the most common known cause of gastroparesis, a condition in which the stomach empties too slowly, according to NIDDK. [8] The Victoza® label says the medicine is not recommended for people with severe gastroparesis. [1]
Steps the leaflets and MedlinePlus describe
- The 0.6 mg first week: the US label says this starting step exists to lower the risk of digestive reactions and does not itself control blood sugar in adults; the next step comes after at least a week. [1]
- Breaks in treatment: the US label restarts at 0.6 mg if more than 3 days have passed since the last dose, because restarting carries its own stomach risk. The EU leaflet and the Canadian patient information give their own missed-dose instructions without the 3-day restart, so follow the rule your prescriber and your leaflet give you. [1][2][3]
- Fluids: the Medication Guide asks you to drink fluids to lower the chance of dehydration. [1]
- Eating: MedlinePlus suggests sitting quietly when you feel sick, eating several small bland meals instead of large ones, sitting up after eating, and avoiding greasy or very spicy food, strong smells, caffeine, alcohol and fizzy drinks. [7]
- Medicines for nausea: MedlinePlus says your provider may suggest one; ask your prescriber or pharmacist rather than adding one on your own. [7]
Stopping, severe reactions and too much medicine
The US label does not give a separate stop rate for nausea. For all stomach and bowel reactions together, 4.3% of adults on Victoza® left the trials because of them, against 0.5% on placebo, and severe digestive reactions were reported by 4.4% on 1.2 mg and 4.2% on 1.8 mg, compared with 1.1% on placebo. [1] In the EU’s long-term trials, nausea alone led 2.8% of people to stop. [2]
Severe nausea and vomiting are also listed among the effects of an overdose. [1] The Medication Guide points you to your provider, the Poison Help line or an emergency room if you take too much. [1]
Victoza® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk A/S.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Vomit that contains blood or looks like coffee grounds | Emergency services (911 or local number) | Emergency | MedlinePlus [6] |
| Severe stomach pain that does not go away, sometimes reaching the back, with or without vomiting | Stop Victoza® and call your provider straight away | Emergency | Medication Guide [1] |
| Nausea with vomiting for more than 24 hours, no fluids kept down for 12 hours, or no urine for 8 hours | Your provider, the same day | Today | MedlinePlus [6]; Medication Guide [1] |
| Possible overdose: severe nausea or vomiting after taking too much | Your provider, Poison Help or an emergency room | Emergency | Medication Guide [1] |
| Nausea that keeps going for more than 48 hours, with weakness or fever | Contact your provider | Today | MedlinePlus [7] |
| Mild nausea that is wearing you down or keeps you from eating | Raise it with your prescriber | At your next appointment | Medication Guide [1] |
